Bella Mehta bella_mehta
4 years ago
KOA can not only ⬆️ morbidity, it also ⬆️s mortality - long term data from OAI - 5K pts, f/u 9 yrs . Greater KL scores (worse Xrays) - greater mortality!
#ACR21 abst#1028 @RheumNow https://t.co/jREmbEN2Ae
Robert B Chao, MD doctorRBC
4 years ago
Exercise does not cause objective signs of increased disease activity in PsA
⭐️11 weeks of High Intensity Interval Training in PsA pts did not show worsening changes in MRI SI joint bone marrow edema.
Abs#1362
@RheumNow
#ACRBest
https://t.co/A3aOEy8Wz0 https://t.co/arPvjsbudm
Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
Clinical Pearl from Dr. @JKolfenbach
⭐️AAV doesn't typically cause hard palate lesions
Instead, consider:
➡️Cocaine-induced midline destructive lesion
➤try to send human neutrophil elastase ab (+ in cocaine use but not in AAV)
➡️Malignancy (NK T-cell lymphoma)
#ACR21 @RheumNow https://t.co/KIEXgCR23c
David Liew drdavidliew
4 years ago
TNFi vs tofacitinib drug survival in RA
(based on two Canadian registries, PS adjusted)
This seems to be my refrain this ACR:
'TNF inhibitors: let's not forget, they're quite good'
#ACR21 ABST1217 @RheumNow @Janetbirdope https://t.co/MyFc6do0JL
Richard Conway RichardPAConway
4 years ago
Dr Koster @MdWarrington @AliDuarteMD open label study baricitinib in relapsing GCA. Well-tolerated and allowed GC discontinuation by 24 weeks in most patients. Encouraging, we need an RCT! Abstr#1396 #ACR21 @RheumNow https://t.co/N2h54MHpIq
Dr. John Cush RheumNow
4 years ago
FDA update: Voclosporin Safety in #SLE RCTs #ACR21 https://t.co/xWCBELxQIc
Dr. John Cush RheumNow
4 years ago
FDA Safety Update - Dr. Nadia Habal reviewed approval of Voclosporin, anifrolumab, Avacopen and approved new indications for multiple drugs #ACR21 https://t.co/lAgQ4d0h2m
Dr. John Cush RheumNow
4 years ago
FDA safety update: OA Stakeholder Workshop June 2021 - Congrats to FDA & AFfor tackling this LARGE unmet need- difficulty in determining benefit in OA (pain, structure, biomarkers?) -more research needed #ACR21 https://t.co/hCWU8OL0Le
Dr. John Cush RheumNow
4 years ago
FDA Update: 3 trials showing Efficacy of Tocilizumab in COVID 19:
1. RECOVERY - lower mortality
2. EMPACTA - Less progression to mech vent or death
3. REMDACTA & COVACTA - did not meet primary endpoints (but not contradictory) FDA Metanalysis of all 4 trials #ACR21 EUA 6/21 https://t.co/9yHu87KGej
Dr. John Cush RheumNow
4 years ago
FDA Update session: Proven Benefit of Baricitinib in Hospitalized COVID-19 from the ACT2 and COV-BARRIER Studies, showing it does not need to be given with Remdesivir (4 mg qd maz 14days) #ACR21 https://t.co/r6crPtu3ZH
Dr. John Cush RheumNow
4 years ago
FDA Update at #ACR21, Dr. Golding reviews the criteria for EUA - Emergency use authorization for new drugs (critically important during COVID-19) Session 8M115 https://t.co/DqmxEIdvWZ D https://t.co/6aQG8yP7RW
Md Yuzaiful Md Yusof Yuz6Yusof
4 years ago
#ACR21 #Abstr1420 A study checking #COVID vaccine response in 90 #lupus pts and 20 HC:
⬇️Titres of Abs in SLE vs controls
💠Factors of poor response: On any DMARDs exc HCQ only (OR 15) and normal dsDNA
📢Important to pause DMARDs in stable SLE @RheumNow https://t.co/USovFkiCRb https://t.co/bn5CC0xRS9
Richard Conway RichardPAConway
4 years ago
Guselkumab improves anaemia in PsA. Appears to correlate with CRP response, ie inflammatory effect. Anaemia resolution associated good outcomes, but many with good outcomes still anaemic. Abstr#1331 #ACR21 @RheumNow https://t.co/LL63Qc0nk5
Mrinalini Dey DrMiniDey
4 years ago
"Managing comorbidities can really improve outcomes for our patients"
@UnaMakris highlights the bio-psycho-social approach to multicomplexity and multimorbidity in our older patients with RA.
#ACR21 @RheumNow https://t.co/TMLqoreogZ
Eric Dein ericdeinmd
4 years ago
#ACR21 Gift of Gab https://t.co/R1e14UA0pQ
Change habits through your words
⭐️Cost of inaction
⭐️Incremental change (ex ⬇️EtOH)
⭐️Follow the crowd!
⭐️Why not try?
Good advice for persuading pts re behavior change, Rx adherence, smoking cessation, vax hesitancy, etc. @Rheumnow https://t.co/9Cd7hAafTr


Poster Hall